Literature DB >> 28004125

Mesenchymal stem cells provide novel insights into ankylosing spondylitis.

Friedrich C Luft1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28004125     DOI： 10.1007/s00109-016-1496-y

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN： 0946-2716            Impact factor:   4.599


× No keyword cloud information.
  12 in total

Review 1.  Ankylosing Spondylitis and Axial Spondyloarthritis.

Authors:  Joel D Taurog; Avneesh Chhabra; Robert A Colbert
Journal:  N Engl J Med       Date:  2016-06-30       Impact factor: 91.245

2.  MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation.

Authors:  Michael S Kim; Christopher J Day; Nigel A Morrison
Journal:  J Biol Chem       Date:  2005-02-17       Impact factor: 5.157

3.  Spontaneous inflammatory disease in HLA-B27 transgenic mice does not require transporter of antigenic peptides.

Authors:  S D Khare; S Lee; M J Bull; J Hanson; H S Luthra; C S David
Journal:  Clin Immunol       Date:  2001-03       Impact factor: 3.969

4.  Serum monocyte chemotactic protein-1 concentrations distinguish patients with ankylosing spondylitis from patients with mechanical low back pain.

Authors:  Consuelo Romero-Sanchez; Hsi-Kai Tsou; Ming-Shiou Jan; Ruey-Hong Wong; I-Chang Chang; John Londoño; Rafael Valle-Oñate; Hwee Siew Howe; David Yu; Bernard P Leung; James Cheng-Chung Wei
Journal:  J Spinal Disord Tech       Date:  2011-05

5.  18F-fluoride PET/CT for detection of axial involvement in ankylosing spondylitis: correlation with disease activity.

Authors:  Luca Idolazzi; Matteo Salgarello; Davide Gatti; Ombretta Viapiana; Elisabetta Vantaggiato; Angelo Fassio; Silvano Adami; Maurizio Rossini
Journal:  Ann Nucl Med       Date:  2016-05-02       Impact factor: 2.668

6.  Imbalance Between Bone Morphogenetic Protein 2 and Noggin Induces Abnormal Osteogenic Differentiation of Mesenchymal Stem Cells in Ankylosing Spondylitis.

Authors:  Zhongyu Xie; Peng Wang; Yuxi Li; Wen Deng; Xin Zhang; Hongjun Su; Deng Li; Yanfeng Wu; Huiyong Shen
Journal:  Arthritis Rheumatol       Date:  2016-02       Impact factor: 10.995

Review 7.  New insights toward the pathogenesis of ankylosing spondylitis; genetic variations and epigenetic modifications.

Authors:  Mahdi Mahmoudi; Saeed Aslani; Mohammad Hossein Nicknam; Jafar Karami; Ahmad Reza Jamshidi
Journal:  Mod Rheumatol       Date:  2016-07-18       Impact factor: 3.023

Review 8.  The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis.

Authors:  Nataliya Yeremenko; Jacqueline E Paramarta; Dominique Baeten
Journal:  Curr Opin Rheumatol       Date:  2014-07       Impact factor: 5.006

9.  IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells.

Authors:  Jonathan P Sherlock; Barbara Joyce-Shaikh; Scott P Turner; Cheng-Chi Chao; Manjiri Sathe; Jeff Grein; Daniel M Gorman; Edward P Bowman; Terrill K McClanahan; Jennifer H Yearley; Gérard Eberl; Christopher D Buckley; Robert A Kastelein; Robert H Pierce; Drake M Laface; Daniel J Cua
Journal:  Nat Med       Date:  2012-07-01       Impact factor: 53.440

10.  C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria.

Authors:  Jan Menne; Dirk Eulberg; Diana Beyer; Matthias Baumann; Frantisek Saudek; Zsuzsanna Valkusz; Andrzej Więcek; Hermann Haller
Journal:  Nephrol Dial Transplant       Date:  2017-02-01       Impact factor: 5.992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.